Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 13Myelodysplastic Syndromes 4Leukemia, Myelomonocytic, Chronic 2Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myeloproliferative Disorders 1Leukemia, Myeloid 1Leukemia, Biphenotypic, Acute 1Leukemia 1

Interventions

Cyclophosphamide 37fludarabine phosphate 27Whole-Body Irradiation 26Cytarabine 26Mycophenolic Acid 22Methotrexate 20Filgrastim 19Peripheral Blood Stem Cell Transplantation 18Cyclosporine 18fludarabine 17venetoclax 15Busulfan 13Tacrolimus 12Granulocyte Colony-Stimulating Factor 12Cord Blood Stem Cell Transplantation 12Thiotepa 11Antilymphocyte Serum 11Melphalan 10Azacitidine 10Dexamethasone 9Cladribine 9Vincristine 8Specimen Handling 8Radiotherapy 8Mitoxantrone 8Methylprednisolone 8Idarubicin 7Cyclosporins 7Clofarabine 7Hydrocortisone 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Leukemia, Biphenotypic, Acute × quizartinib × Clear all
NCT04047641 2025-12-17

Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
80 enrolled
Other hematologic neoplasm

Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡